H.R. 4030: Treatment Continuity Act of 2025

This bill, known as the Treatment Continuity Act of 2025, aims to amend the Public Health Service Act to enhance treatment options for individuals with substance use disorders and serious mental illnesses. Here are the key components of the bill:

Amendments to Treatment Services

The bill proposes the following changes:

• Inclusion of Serious Mental Illness: The term "serious mental illness" is added explicitly alongside "substance use disorder" to ensure that both conditions are treated with equal importance.
• Access to Long-Acting Injectable Medications: The bill seeks to provide access to long-acting injectable medications that are approved by the Food and Drug Administration (FDA) for individuals suffering from substance use disorders or serious mental illnesses.
• Supportive Services: It includes provisions for lab testing and counseling that support treatment for both substance use disorders and serious mental illnesses.
• Professional Training: The bill emphasizes the need for training healthcare providers on the use of long-acting injectable medications, along with associated clinical services such as counseling.

Reporting Requirements

The Secretary of Health and Human Services is required to submit an annual report to Congress on the program's outcomes. This report must include:

• Details on the progress made toward meeting treatment requirements as assessed by clinicians.
• Evaluation of the effectiveness of the services provided.

Grants Applicability

The amendments made by this bill apply to grants administered under section 509 of the Public Health Service Act that are made after the enactment of this legislation. This means that future funding for programs will reflect the changes outlined in the bill.

Overall Aim

The overall aim of the Treatment Continuity Act of 2025 is to improve and expand access to evidence-based treatments for individuals facing substance use disorders and serious mental illnesses, ensuring that these groups receive the comprehensive care they need.

Relevant Companies

• PFE (Pfizer Inc.): Pfizer is involved in the development of various medications, including long-acting injectables that can be used to treat certain mental health conditions and substance use disorders. If this legislation increases the demand for such treatments, it could impact their market performance.
• MRK (Merck & Co., Inc.): Merck also develops medications that could be classified under the bill's provisions. An increase in access to treatments could potentially increase their sales in this sector.
• LLY (Eli Lilly and Company): Eli Lilly produces medications for mental illness, and this bill's emphasis on treatment access could affect their business strategies and sales for such products.